Department of Global Health, Koç University Graduate School of Health Sciences, Istanbul, Turkey.
Department of Gynecologic Oncology, Koc University School of Medicine, Istanbul, Turkey.
Arch Gynecol Obstet. 2024 Jun;309(6):2267-2278. doi: 10.1007/s00404-024-07463-9. Epub 2024 Mar 17.
The primary aim was to analyze the current practices on the use of operative hysteroscopy for preserving fertility in patients diagnosed with endometrial cancer and premalignancies. Our secondary objectives included investigating medical therapy and analyzing reported pregnancy-related outcomes subsequent to fertility preservation procedures.
We performed a semi-systematic literature review on PubMed, employing pertinent terms related to hysteroscopy, fertility preservation, and endometrial cancer and premalignancies. Patients undergoing operative hysteroscopy with or without following medical treatment were included. We adhered to the PRISMA 2020 statement and utilized Covidence software to manage our systematic review. We performed a pooled analysis on various outcomes.
Our final analysis included 15 studies evaluating 458 patients, where 238 (52.0%) were diagnosed with endometrial cancer, and 220 (48.0%) had endometrial premalignancies. With 146 pregnancies in our study, the overall pregnancy rate was 31.9%. Among these, 97 resulted in live births, accounting for 66.4% of the reported pregnancies. In terms of medical treatment, various forms of progestins were reported. Complications or adverse effects related to operative hysteroscopy were not reported in more than half of the studies. Among those studies that did report them, no complications nor adverse effects were documented. After hysteroscopic resection, complete response to medical treatment has been reported in 65.5% of the overall cases.
Our review sheds light on the contemporary landscape of operative hysteroscopy for fertility preservation in endometrial cancer and premalignancies. Future studies should include the integration of molecular classification into fertility-preserving management of endometrial malignancies to offer a more personalized and precise strategy.
本研究旨在分析目前在诊断为子宫内膜癌和癌前病变的患者中采用手术宫腔镜保留生育力的实践情况。我们的次要目标包括研究药物治疗,并分析随后进行生育力保存手术后的妊娠相关结局。
我们在 PubMed 上进行了半系统性文献回顾,使用与宫腔镜、生育力保存和子宫内膜癌和癌前病变相关的相关术语。纳入接受手术宫腔镜检查并(或)随后进行药物治疗的患者。我们遵循 PRISMA 2020 声明,并使用 Covidence 软件管理我们的系统评价。我们对各种结局进行了汇总分析。
我们的最终分析纳入了 15 项研究,共评估了 458 例患者,其中 238 例(52.0%)诊断为子宫内膜癌,220 例(48.0%)为子宫内膜癌前病变。在我们的研究中,共有 146 例妊娠,总妊娠率为 31.9%。其中,97 例为活产,占报告妊娠的 66.4%。在药物治疗方面,报告了各种形式的孕激素。超过一半的研究未报告与手术宫腔镜相关的并发症或不良反应。在报告这些并发症或不良反应的研究中,未记录到任何并发症或不良反应。在宫腔镜切除后,总体病例中有 65.5%报告对药物治疗有完全反应。
本综述阐明了目前在子宫内膜癌和癌前病变中采用手术宫腔镜保留生育力的现状。未来的研究应将分子分类纳入子宫内膜恶性肿瘤的生育力保存管理中,以提供更个体化和精准的策略。